Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

CONCLUSIONS: Taken together, our data highlight that extending the dosing interval of ocrelizumab does not lead to increased repopulation of effector B cells. We show that the increase of CD20 expression on B cell subsets in EID might lead to longer depletion or less repopulation of B cells after the next infusion of ocrelizumab. Lastly, even though extending the ocrelizumab interval dosing alters B cell repopulation, it does not affect the clinical efficacy of ocrelizumab in our cohort of patients with MS.PMID:37752582 | DOI:10.1186/s12974-023-02900-z

Source: Cancer Control - September 26, 2023 Category: Cancer & Oncology Authors: Carla Rodriguez-Mogeda Zo ë Y G J van Lierop Susanne M A van der Pol Loet Coenen Laura Hogenboom Alwin Kamermans Ernesto Rodriguez Jack van Horssen Zo é L E van Kempen Bernard M J Uitdehaag Charlotte E Teunissen Maarten E Witte Joep Killestein Helga E d Source Type: research